The World Health Organization suggested that supervised digital support, such as activity trackers and online games that encourage movement, is an optional tool to support physical activity

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

Early Alzheimer's symptoms such as hearing impairment can reduce engagement in physical activity, triggering accelerated cognitive and memory decline.

A UK study of 1,139 people over age 50 found that moderate to vigorous physical activity reduced dementia risk by 34% to 50% over eight to ten years.

Physically active individuals are also more likely to maintain heart health, eat well, refrain from smoking, and experience fewer financial stresses.

Brain health benefits against Alzheimer's tau protein accumulation appeared at 3,000 steps daily, with an optimal protective plateau between 5,000 and 7,500 steps daily.

A study tracking almost 300 older adults found that physical activity did not reduce toxic amyloid plaques, but reduced signs of dementia by almost half in more active participants.

In older adults with early brain signs of Alzheimer's, physical activity reduced the accumulation of misfolded tau proteins in specific brain areas over nine to 11 years, according to a study tracking participants with pedometers.

Safety concerns, fear of falling, and colder weather present major barriers that prevent older adults from maintaining protective outdoor walking routines.

A 2022 UK study tracking 78,430 people for seven years using wrist accelerometers found a 25% reduction in dementia risk at 3,800 daily steps, rising to 50% at 9,800 steps.

Cardiovascular and stroke risk factors including elevated cholesterol, poor sleep, high blood pressure, and diabetes increase dementia risk alongside physical inactivity.

More young people need to get their brain scanned

Satralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signaling

Thyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidism

Satralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye disease

Prior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026

Satralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory condition

Satralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare provider

Although satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2

On October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye disease

The FDA approval of satralizumab for thyroid eye disease was based on data from the global phase 3 SatraGO program, which enrolled 258 patients across 19 countries